Progress towards new treatments for human African trypanosomiasis

Garcia-Salcedo, J. A., Munday, J. C. , Unciti-Broceta, J. D. and De Koning, H. P. (2014) Progress towards new treatments for human African trypanosomiasis. In: Magez, S. and Radwanska, M. (eds.) Trypanosomes and Trypanosomiasis. Springer, pp. 217-238. ISBN 9783709115558 (doi:10.1007/978-3-7091-1556-5_9)

Garcia-Salcedo, J. A., Munday, J. C. , Unciti-Broceta, J. D. and De Koning, H. P. (2014) Progress towards new treatments for human African trypanosomiasis. In: Magez, S. and Radwanska, M. (eds.) Trypanosomes and Trypanosomiasis. Springer, pp. 217-238. ISBN 9783709115558 (doi:10.1007/978-3-7091-1556-5_9)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1007/978-3-7091-1556-5_9

Abstract

The treatment of African trypanosomiasis has essentially remained unchanged for decades. A mountain of excellent work has been produced on many aspects of trypanosome biochemistry, biology, genetics, etc., but this has not translated into new therapies, although the disease burden has steadily increased through the latter half of the twentieth century. The only new drug to be introduced in the last 50 years or so is eflornithine, in the late 1970s, for the treatment of late-stage gambiense sleeping sickness only. However, this was in many ways unsatisfactory and melarsoprol remained the first-line treatment for late-stage sleeping sickness until an alarming increase in treatment failures necessitated change. Since the emerging sleeping sickness epidemic became widely recognised, around the year 2000, needs-driven development of new drugs, and the preservation of the production of old drugs, has been the result of dedicated work by organisations such as the World Health Organisation, the Drugs for Neglected Diseases initiative (DNDi), the Access to Essential Medicines campaign, and the Consortium for Parasitic Drug Development (CPDD) among others, much of it in partnership with academia and the pharmaceutical industry. This has already resulted in milestones such as the donations of free treatments by producers; improved drug distribution, case finding and clinical care; an improved 10-day melarsoprol treatment; the first clinical trial for an oral sleeping sickness drug—pafuramidine and the introduction of eflornithine–nifurtimox combination therapy to begin replacing melarsoprol. While these efforts have undoubtedly contributed to reducing the disease burden in central Africa, newer treatments are still very necessary, especially as most current treatments are threatened by drug resistance. Here, we review recent advances in understanding drug resistance mechanisms, progress towards new drugs, and new delivery systems to improve efficacy.

Item Type:Book Sections
Status:Published
Glasgow Author(s) Enlighten ID:Munday, Dr Jane and De Koning, Professor Harry
Authors: Garcia-Salcedo, J. A., Munday, J. C., Unciti-Broceta, J. D., and De Koning, H. P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Publisher:Springer
ISBN:9783709115558

University Staff: Request a correction | Enlighten Editors: Update this record